GridAI Technologies Corp.

GRDX
About the company

GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.

Country: United StatesPrice: $3.74Market Cap: $33.2M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

$33638185.98

+899416635.1% vs price

Models with upside

1 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILPASSFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/A+100.0%N/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-05-01

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-05-01

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-05-01

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-05-01

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-06-30

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-05-01

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-05-01

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-05-01

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-21

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 6✗ 22▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.2x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-20.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-20.6%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.2x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-96.2%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.2x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low366% of trailing low ($1.02)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-62.01%; #5166/6340 (top 81.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.4475; #3072/6449 (top 47.6%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0011; #5020/5247 (top 95.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+78.95%; #437/6202 (top 7.0%)
      ✓OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-58.5M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-32.4M
      ✗LynchPositive and growing
      Operating Cash Flow$-5.7M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-11.75%, ROA=-13.17%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/7 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/11 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-1.63 (2015) -> $-4.16 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/11 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth
      ✗Ackman>= 5%
      Positive EPS Growth Frequency3/5 years with positive EPS growth
      ✓AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag GRDX's efficiency

      Current Ratio0.16
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-705.2%
      ✗Buffett> 10%
      ROIC - WACC-715.2%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)
      ✗Greenblatt> 25%
      Current Ratio Change YoY3.03 -> 0.17
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.16
      ✗Dreman> 1.5
      Return on Invested Capital-106.6%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-295.5%; FY2024: ROIC=unavailable; FY2025: ROIC=-20.7%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/3 years above 12% (latest -20.7%)
      ✗SleepROIC > 12% in a majority of years
    • Profitability6% pass✓ 3✗ 32▾

      15 of 16 flag GRDX's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/12 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/12 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-325.8%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-58.5M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)3.16
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-138.6%
      ✗Lynch> 15%
      EBIT / Enterprise Value-20.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-20.6%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-13.17%
      ✗PiotroskiROA > 0
      ROA Change YoY-21.14% -> -13.17% (delta: +7.98%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-11.75%, ROA=-13.17%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-18316.8%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-138.6%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.2x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-332.5% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/11 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-19540.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-138.6%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trend
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-62.01%; #5166/6340 (top 81.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets-1.35%; #3564/3702 (top 96.3%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-138.55%; #4746/5226 (top 90.8%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-1.7903; #5432/5884 (top 92.3%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts13% pass✓ 2✗ 13▾

      Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 4)✗DremanFAIL (2/11)✓MungerPASS (2/4)✗PabraiFAIL (1/3)✗AkreFAIL (1/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✗SleepFAIL (0/6)✗AsnessFAIL (Rank #1774/2370 (Top 74.9%))✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage42% pass✓ 8✗ 7▾

      7 of 12 flag GRDX's debt & leverage — Graham, Buffett, Lynch +4 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.08, IC: N/A
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.11
      ✓Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.16
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.11
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.11
      ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.11
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.1127; #1337/4210 (top 31.8%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($33.2M)
    Revenue: $36251.00
    Net Income: $6.4M+64.6% YoY

    Financial Snapshot

    Operating Margin-19540.0%
    Return on Equity-25.6%
    Debt / Equity0.08
    Current Ratio0.17
    EPS (Diluted)$-4.16

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, net income, operating income, ebit, pre tax income.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-05-01
    FY 2024
    Sources
    • 10-K · 2025-04-01
    FY 2023
    Sources
    • 10-K · 2024-03-29
    FY 2022
    Sources
    • 10-K · 2023-03-20
    FY 2021
    Sources
    • 10-K · 2022-03-31
    Market Cap$33.2Mcurrent----$5.1Mest.$7.1Mest.$5.3Mest.$323.6Mest.$144.0Best.
    Revenue--$85.9K$38.2K$36.3K--------
    Operating Income-$22.3M↓390%-$13.1M↓1952%-$3.6M↓340%-$7.1M↑55%-$15.6M↑1%-$15.8M↓24%-$12.7M↑79%-$59.1M
    Net Income-$20.6M↓21%-$13.0M↓1206%-$3.4M↓173%-$6.4M↑65%-$18.1M↓14%-$15.8M↓8%-$14.6M↑75%-$58.5M
    EPS (Diluted)--$-2.01↓857%$-0.82↓193%$-4.16↑22%$-5.33↑89%$-47.88↓128%$-21.00↓122%$-9.47
    Gross Margin—-42.5%-1606.3%-1813.6%————
    Operating Margin—-15262.4%-9460.1%-19540.0%————
    ROE-138.6%↓151%——-25.6%↓106%465.8%↑206%-438.4%↑18%-533.5%↓171%748.4%
    Total Debt$1.7M↑139%$1.7M↑139%$2.4M↑236%$2.0M--$612.8K↑2%$603.5K↓6%$641.2K
    Shareholders' Equity$14.9M↑336%$14.9M↑336%$23.6M↑552%$24.9M↑743%-$3.9M↓208%$3.6M↑31%$2.7M↑135%-$7.8M
    Current Ratio0.16↓94%0.16↓94%0.16↓95%0.17↓94%3.03↑92%1.58↑15%1.37↑79%0.77
    Debt / Equity0.11↑201%0.11↑201%0.10↑174%0.08—0.17↓23%0.22↑368%-0.08
    Operating Cash Flow-$8.1M↓181%-$1.5M↓2642%-$1.8M↓118%-$5.7M↑38%-$9.2M↑26%-$12.4M↑45%-$22.3M↑31%-$32.3M
    Free Cash Flow---------------$32.4M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    GRDX vs Peers — Financial Grading

    Revenue$36251.00Bottom 25%
    Net Income$6.4MMedian
    ROE-25.6%Bottom 25%
    D/E0.08Top 25%
    Op. Margin-19540.0%Bottom 25%
    Curr. Ratio0.17Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11